Cochrane · systematic review · CD010483
Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy
Brigo, F, Igwe, SC, Bragazzi, NL · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: children with SMEI
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
≥ 50% reduction in seizure frequency 2‐month | RR 10.4 [2.64, 40.87] | 2 studies · 64 participants | Moderate Downgraded: risk of bias, imprecision |
Seizure freedom 2‐month | RR 7.93 [1.52, 41.21] | 2 studies · 64 participants | Moderate Downgraded: risk of bias, imprecision |
Proportion of dropouts 2‐month | RR 0.24 [0.06, 1.03] | 2 studies · 64 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse effects | RR 3.73 [1.81, 7.67] | 1 study · 41 participants | Low Downgraded: risk of bias, imprecision |